» Articles » PMID: 15004239

Tyrosine Phosphorylation of Sprouty Proteins Regulates Their Ability to Inhibit Growth Factor Signaling: a Dual Feedback Loop

Overview
Journal Mol Biol Cell
Date 2004 Mar 9
PMID 15004239
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Sprouty proteins are recently identified receptor tyrosine kinase (RTK) inhibitors potentially involved in many developmental processes. Here, we report that Sprouty proteins become tyrosine phosphorylated after growth factor treatment. We identified Tyr55 as a key residue for Sprouty2 phosphorylation and showed that phosphorylation was required for Sprouty2 to inhibit RTK signaling, because a mutant Sprouty2 lacking Tyr55 augmented signaling. We found that tyrosine phosphorylation of Sprouty2 affected neither its subcellular localization nor its interaction with Grb2, FRS2/SNT, or other Sprouty proteins. In contrast, Sprouty2 tyrosine phosphorylation was necessary for its binding to the Src homology 2-like domain of c-Cbl after fibroblast growth factor (FGF) stimulation. To determine whether c-Cbl was required for Sprouty2-dependent cellular events, Sprouty2 was introduced into c-Cbl-wild-type and -null fibroblasts. Sprouty2 efficiently inhibited FGF-induced phosphorylation of extracellular signal-regulated kinase 1/2 in c-Cbl-null fibroblasts, thus indicating that the FGF-dependent binding of c-Cbl to Sprouty2 was dispensable for its inhibitory activity. However, c-Cbl mediates polyubiquitylation/proteasomal degradation of Sprouty2 in response to FGF. Last, using Src-family pharmacological inhibitors and dominant-negative Src, we showed that a Src-like kinase was required for tyrosine phosphorylation of Sprouty2 by growth factors. Thus, these data highlight a novel negative and positive regulatory loop that allows for the controlled, homeostatic inhibition of RTK signaling.

Citing Articles

Targeting exosomes enveloped EBV-miR-BART1-5p-antagomiRs for NPC therapy through both anti-vasculogenic mimicry and anti-angiogenesis.

Wang J, Liu Y, Zhang Y, Li X, Fang M, Qian D Cancer Med. 2023; 12(11):12608-12621.

PMID: 37097161 PMC: 10278492. DOI: 10.1002/cam4.5941.


A dominant negative mutation uncovers cooperative control of caudal Wolffian duct development by Sprouty genes.

Altes G, Vaquero M, Cuesta S, Anerillas C, Macia A, Espinet C Cell Mol Life Sci. 2022; 79(10):514.

PMID: 36098804 PMC: 9470706. DOI: 10.1007/s00018-022-04546-1.


Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells.

Kamptner A, Mayer C, Sutterluty H Int J Mol Sci. 2021; 22(21).

PMID: 34769378 PMC: 8585105. DOI: 10.3390/ijms222111944.


Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling.

Szybowska P, Kostas M, Wesche J, Haugsten E, Wiedlocha A Cells. 2021; 10(6).

PMID: 34071546 PMC: 8226934. DOI: 10.3390/cells10061342.


Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.

Ferguson H, Smith M, Francavilla C Cells. 2021; 10(5).

PMID: 34068954 PMC: 8156822. DOI: 10.3390/cells10051201.


References
1.
Lee S, Schloss D, Jarvis L, Krasnow M, Swain J . Inhibition of angiogenesis by a mouse sprouty protein. J Biol Chem. 2000; 276(6):4128-33. DOI: 10.1074/jbc.M006922200. View

2.
Tsygankov A, Teckchandani A, Feshchenko E, Swaminathan G . Beyond the RING: CBL proteins as multivalent adapters. Oncogene. 2001; 20(44):6382-402. DOI: 10.1038/sj.onc.1204781. View

3.
Weinstein D, Marden J, Carnevali F, Hemmati-Brivanlou A . FGF-mediated mesoderm induction involves the Src-family kinase Laloo. Nature. 1998; 394(6696):904-8. DOI: 10.1038/29808. View

4.
Fong C, Leong H, Wong E, Lim J, Yusoff P, Guy G . Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J Biol Chem. 2003; 278(35):33456-64. DOI: 10.1074/jbc.M301317200. View

5.
Hall A, Jura N, DaSilva J, Jang Y, Gong D, Bar-Sagi D . hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr Biol. 2003; 13(4):308-14. DOI: 10.1016/s0960-9822(03)00086-1. View